Aggressive approach and outcome in patients presenting atrial fibrillation and hypertension by Conti, A. et al.
International Journal of Cardiology xxx (2011) xxx–xxx
IJCA-13986; No of Pages 5
Contents lists available at SciVerse ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdAggressive approach and outcome in patients presenting atrial fibrillation
and hypertension
Alberto Conti a,⁎, Erica Canuti a, Yuri Mariannini a, Maurizio Zanobetti a, Francesca Innocenti a,
Barbara Paladini b, Giuseppe Pepe b, Luigi Padeletti c, Gian Franco Gensini c
a Emergency Medicine, Department of Medical and Surgical Critical Care, University of Florence and Careggi University Hospital, Florence, Italy
b Emergency Department, Careggi University Hospital, Florence, Italy
c Department of Heart and Vessel Disease, University of Florence and Careggi University Hospital, Florence, Italy⁎ Corresponding author at: Emergency Medicine, Depa
and Surgery, Careggi University Hospital, Florence, Italy. Te
055 7947934.
E-mail address: aaaconti@hotmail.com (A. Conti).
0167-5273/$ – see front matter © 2011 Published by El
doi:10.1016/j.ijcard.2011.09.074
Please cite this article as: Conti A, et al, Aggr
diol (2011), doi:10.1016/j.ijcard.2011.09.07a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 August 2011
Accepted 17 September 2011
Available online xxxx
Keywords:
Hypertension
Atrial fibrillation
Emergency medicine
Pharmacological treatment
Electrical treatment
Intensive approach
Aim: Aggressive approach in patients presenting atrial fibrillation (AF) and hypertension could result in
improving rhythm control and reducing admission.
Methods: Out of 3475 patients presenting AF, those with hypertension (n=1739, 52%) underwent standard
(n=591, group 1, years 2004–2005) or aggressive pharmacological and electrical approach (n=1148, group
2, years 2006–2009). Overall, in 1071 patients AF duration was less than 48 h. Primary endpoint was rhythm
conversion; secondary endpoints were modalities of rhythm conversion and reduction of admissions.
Results: At univariate andmultivariate analyses, AF lasting less than 48 h, absence of comorbidities and younger
age were independent predictors of sinus rhythm; conversely, lack of sinus rhythm, older age, AF lasting more
than 48 h and comorbidities were independent predictors of hospitalization. Overall, 55% of patients achieved
sinus rhythm in group 1 versus 62% in group 2 (p=0.018). Interestingly, in patients with AF lasting less than
48 h, 89% achieved sinus rhythm, more likely by class 1C than by class III antiarrhythmic drugs (pb0.001). Over-
all reduction of admission accounts for 60%; 50% of patients need admission in group 1 versus 29% in group 2
(pb0.001).
Conclusions: Aggressive pharmacological and electrical approach in patients presenting AF and hypertension
significantly improved rhythm conversion overall up to 62%. Patients with AF lasting less than 48 h eventually
achieved sinus rhythm up to 89%, mostly by class IC antiarrhythmic drugs. Admissions eventually reduced up to
60%.
© 2011 Published by Elsevier Ireland Ltd.1. Introduction
In emergency settings, effective therapeutic management of atrial
fibrillation (AF) is not yet clear, because of lack of understanding of
several pathophysiological aspects of arrhythmia and because the
existing possibility of the underlying presence of structural heart
disease to which several pharmacological side effects are related.
Moreover, to date there has been no convincing evidence that antiar-
rhythmic or antihypertensive therapy and ‘rhythm control’ is better
than the rate control approach [1–3]. However, recent data have
shown therapeutic success might be associated with rhythm-control
and clinical outcomes driven by hospitalizations for arrhythmia and
other comorbidities [4]. Atrial fibrillation is established to share
strong epidemiological associations with a large panel of risk factors
including advanced age, male sex, diabetes mellitus and especially
hypertension or with several diseases including heart failure,rtment of Critical Care Medicine
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[5,6]. Atrial fibrillation could also be the effect of an underlying
‘masked’ disorder associated with metabolic syndrome and its com-
ponents, sleep apnea, inflammation, and aspects of lifestyle as alcohol
consumption and physical activity. Eventually, in some patients with
AF, no underlying pathology is present and the etiology remains un-
known [7]. Detection of the underlying disorder may result in imple-
mentation of effective treatment that could improve outcomes, but
the presence of structural heart disease as in patientswith hypertension
should not to be considered as absolute contraindication to aggressive
approach and rhythm control. The aim of the present study was to
evaluate if aggressive approach in patients with AF and hypertension
without moderate to severe structural heart disease could result in
improving rhythm control and eventually reducing admission in a
large series of patients presenting to the Emergency Department [8].2. Materials and methods
The study enrolled AF patients presenting to the Emergency Department of the
tertiary care teaching hospital, in Florence, Italy. Facilities for triage of patients with
suspected dysrhythmia included an Observation Unit with 6 monitor equipped bedse in patients presenting atrial fibrillation and hypertension, Int J Car-
Table 1
Baseline clinical characteristics of patients with atrial fibrillation and hypertension
enrolled in the study (n=1739).
Clinical
characteristics
Total
(n=1739)
Group 1
(n=591)
p Group 2
(n=1148)
Age (years s.d.) 72 11 72±11 0.478 73±11
Gender (male) 793 (46%) 247 (42%) 0.022 546 (48%)
Diabetes mellitus 202 (12%) 57 (10%) 0.069 145 (13%)
Comorbidities 747 (43%) 277 (47%) 0.019 470 (41%)
AFb48 h 1071 (62%) 320 (54%) b0.001 751 (65%)
Sinus rhythm 1039 (60%) 330 (56%) 0.018 709 (62%)
Discharge 1110 (64%) 296 (50%) b0.001 814 (71%)
2 A. Conti et al. / International Journal of Cardiology xxx (2011) xxx–xxxand dedicated personnel (resident, faculty, and cardiologist on call). Coded diagnoses
are entered into an electronic medical chart, allowing easy selection of all patients
with a diagnosis of interest. Data were collected from January 2004 to December 2010.
2.1. Patient selection
Inclusion criteria were the presence of AF documented by ECG. Consecutive
patients presenting to the Emergency Department complaining of palpitations or
malaise were considered and those with AF documented by ECG were evaluated and
enrolled in the study. Exclusion criteria were ageb18 years, Killip Class ≥2, New York
Heart Association functional class≥ III, clinically detectable ongoing complications like
acute coronary syndrome, stroke and pulmonary or peripheral embolism, and hemody-
namic instability. Patients withmoderate to severe structural heart diseasewere excluded
from the study. All patients gave their consent for study participation. The study was
conducted according to good clinical practice and the Helsinki Principles.
2.2. Definition of subtype of AF, structural heart disease and comorbidities
Paroxysmal AF was defined by electrocardiographic evidence of AF followed by
subsequent ECG showing sinus rhythm or clinical documentation by a physician of par-
oxysmal AF; persistent AF was defined when lasting longer than 7 days or when termi-
nated by therapeutic treatment; permanent AF (or chronic AF) was defined in the
presence of serial electrocardiograms showing only AF and no interim evidence of sinus
rhythm; solitary AF was defined by AF in the absence of overt cardiovascular disease or
precipitating illness [9]. Systemic hypertension was defined by need for antihypertensive
therapyor the presence of systolic blood pressure≥140 mmHgor diastolic blood pressure
≥90 mmHg. Coronary artery disease was defined by angiographic findings of stenosis
N50% in any of the 3 main arterial distributions, effort angina, or history of myocardial
infarction. Moderate to severe valvular heart disease was considered in the presence of
substantial murmur on physical heart examination, or by history of documented prior
valve repair/replacement or by echocardiography confirmation. Congestive heart failure
was defined by a physician's diagnosis or byneed for treatmentwith dedicated drug treat-
ment. Carotid artery disease referred to the presence of stenosisN50% in the carotid
arteries based on neurovascular imaging or previous intervention. Stroke included devel-
opment of any type of stroke, as defined by clinical documentation of the diagnosis with
or without confirmatory findings on imaging studies. Diabetes mellitus was defined by a
physician's diagnosis or by need for treatment with insulin or oral hypoglycemic agents.
Chronic obstructive pulmonary disease and dysthyroidismwere defined by a physician's
diagnosis as documented in the medical records. Abnormal kidney function was defined
as the presence of equivalent serum creatinine ≥200 mmol/L or renal transplant or the
presence of chronic dialysis. ‘Abnormal liver function’ was defined as chronic hepatic
disease (e.g. cirrhosis) or biochemical evidence of significant hepatic derangement (e.g.
bilirubinN2× upper limit of normal, in association with aspartate aminotransferase/
alanine aminotransferase/alkaline phosphatase N3× upper limit normal, etc.). Also
patientswith other chronic diseases (e.g. immunity disorders and cancer) and eventually
at short-term life expectancy were considered.
2.3. Management of patients and study protocol
All patients underwent evaluation with medical history, physical examination,
blood tests, serial ECGs and plasma levels of Troponin I. Chest radiograph, blood gas
analysis and echocardiogram were performed according to the clinical conditions.
Patients with AF onset less than 48 h and without moderate to severe structural heart
disease were considered eligible for rhythm control and received within the first-line 6-
hour period i.v. bolus (in a few minutes) Flecainide (2 mg/kg), Propafenone (2 mg/kg),
or Amiodarone (5 mg/kg), [9–13]. Patients who did not recover sinus rhythm could be
submitted to a second dose of drugs previously given, eventually followed by oral admin-
istration up to 24 h of Flecainide (2 mg/kg plus 100 mg twice a day), Propafenone
(2 mg/kg plus 150 mg three times a day), or Amiodarone (5 mg/kg plus 200 mg twice a
day). After the first or second-line approach, patients could be submitted to early or elec-
tive electrical conversion (previous transesophageal echocardiography or after 3 weeks
anticoagulation, respectively). After DC shock, patients were observed for a period of 6 h
to promptly detect adverse events. No randomization was used and the therapeutic
approach was at the discretion of the physician on duty [9].
2.4. Patients considered for enrollment in the study
Two groups of patients were considered. Group 1 included those patients presenting
to the Emergency Department between January 2004 and December 2005 managed
with standard approach; conversely group 2 included those patients presenting between
January 2006 and December 2009 managed with aggressive treatment strategy in the
Intensive ObservationUnit and eventually additional Outpatient Clinic. Treatment strategy
included intensivepharmacological treatment followedbyelectrical treatment as required.
Hypertension, diabetes mellitus, comorbidities, AF duration (less or more than 48 h),
quality of therapeutic approach and rhythm conversion or lack of rhythm control were
analyzed.
2.4.1. Endpoint
Primary endpoint included rhythm conversion; secondary endopoints included
modalities of rhythm conversion and reduction of admissions.Please cite this article as: Conti A, et al, Aggressive approach and outcom
diol (2011), doi:10.1016/j.ijcard.2011.09.0742.5. Statistical analysis
Summary data are expressed as mean±SD. Statistical comparisons of demographic
and clinical features among the 2 groupswere performedusingχ2 test for non parametric
variables, as required. Analysis of variance was used for parametric variables. Univariate
and multivariate logistic regression were used to define independent predictors of hospi-
talization. P values are 2 sided. A p value b0.05 was considered statistically significant.
Calculations were performed with version 17, SPSS statistical package (SPSS Inc, Chicago,
IL).3. Results
From January 2004 to December 2009, 3475 AF patients presenting
to the Emergency Department (1.1% of total visits per year) were con-
sidered for enrolment in the study. Those with hypertension (1739,
52%) and without moderate to severe structural heart disease were
enrolled and stratified into two groups: group 1 (years 2004–2005)
included 591 patients and group 2 (years 2006–2009) included 1148
patients. Baseline clinical characteristics of enrolled patients are shown
in Table 1. In our series approximately two-third of patients presented
AF lasting less than 48 h; one-half showed male gender and one-half
comorbidities; mean age was 72 years. Due to the prospective obser-
vational design of the study, differences existed among clinical char-
acteristics of the two groups of patients including male gender,
comorbidities and duration of AF. Mean age was the same (Table 1).
At univariate and multivariate analyses, AF lasting less than 48 h,
absence of comorbidities and younger agewere independent predictors
of sinus rhythm (Table 2). Conversely, lack of sinus rhythm, older age,
AF lasting more than 48 h, presence of comorbidities and diabetes
were independent predictors of hospitalization (Table 3).
Overall, 1039 (60%) patients achieved sinus rhythm; we found a
strong association between lower decades of age and conversion
to sinus rhythm in patients with atrial fibrillation and hypertension
enrolled in the study (Fig. 1). However, 55% patients achieved sinus
rhythm in group 1 versus 62% in group 2 (p=0.018, Table 4). Sponta-
neous, electrical or pharmacological conversion account for 24%, 8%
and 68% in group 1 versus 30%, 21% and 49% in group 2 (pb0.001,
Table 4). Interestingly, out of 1071 patients with AF lasting less than
48 h, 950 (89%) achieved sinus rhythm as follows: 249 (26%) sponta-
neously, 160 (17%) by electrical conversion and 541 (57%) by inten-
sive pharmacological approach (394 with class 1C and 147 with
class III antiarrhythmic drugs, 73% and 27%, respectively, pb0.001,
Fig. 3). In this subset of patients, spontaneous, electrical or pharmaco-
logical conversion account for 23%, 7% and 70% in group 1 versus 28%,
21% and 51% in group 2 (pb0.001). In both groups, patients more
likely achieved sinus rhythm by class 1C as compared to class III anti-
arrhythmic drugs (pb0.001, Table 5). Overall, only 36% (n=629) pa-
tients need admission; 50% in group 1 versus 29% in group 2; thus
reduction of admission accounts for up to 60% (pb0.001, Fig. 2). In
our series, we found a strong association between higher decades of
age and admission to hospital (Fig. 4).e in patients presenting atrial fibrillation and hypertension, Int J Car-
Table 2
Association between clinical variables and sinus rhythm at univariate and multivariate
analyses.
Univariate analysis Multivariate analysis
OR Confidence
interval 95%
p OR Confidence
interval 95%
p
AF lasting
b48 h
51.077 38,132–68,436 b0.001 47.890 35,626–64,377 b0.001
Comorbidities 1.911 1.573–2.322 b0.001 1.687 1.247–2.264 b0.001
Age 0.961 0.951–0.970 b0.001 0.962 0.969–0.996 b0.001
Diabetes
mellitus
1.834 0.1366–2.463 b0.001 – – –
Male gender 0.960 0.792–1.164 0.680 – – –
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Fig. 1. Association between decades of age and sinus rhythm in patients with atrial
fibrillation and hypertension enrolled in the study (n=1739).
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Detection of the underlying AF disorder even clinically ‘masked’
could result in implementing effective treatment and improving
prognosis [6,8,14]. Suggestion resulted in reducing aggressive ap-
proach to AF patients. Indeed in the past decades clinical pathways
pursued conversion to sinus rhythm, in patients presenting AF, when
no structural heart disease was detected. At the same time this condi-
tion was considered to be associated essentially with isolated AF
which accounted for almost 30% of all AF cases [1,6,15]. However, recent
studies have demonstrated that lone AF is quite a rare disorder. Scien-
tists from the Mayo Clinic of Olmsted County in the American state of
Minnesota examined, between 1950 and 1980, 3623 patients with a
first episode of AF and followed up them until 2003. Data revealed
that only 2% of the total population of patients with AF really presented
isolatedAFwith no concomitant heart disease, diabetesmellitus, hyper-
tension or noncardiac disease that potentially could shorten life expec-
tancy [7]. In the Framingham Heart Study, hypertension and diabetes
were the sole cardiovascular risk factors to be predictive of AF after
controlling for age and other predisposing conditions [16]. Thus, the
role of hypertension as risk factor for AF is established; however,
despite its leading importance as a highly prevalent and modifiable
risk factor, only a few data are available regarding predictors and out-
come of AF in hypertension. Extrapolations of results to uncomplicated
hypertensive subjects with possible coexistence of LV hypertrophy
could lead to improve aggressive treatment to pursue sinus rhythm
[5,6,17].
The present study shows approximately two-third of patients pre-
senting AF and hypertension achieved sinus rhythm when submitted
to aggressive approach versus standard approach (p=0.018, Table 2).
In addition, four-fifth of patients with AF lasting less than 48 h
achieved sinus rhythm without difference between groups; patients
more likely achieved sinus rhythm by class 1C than by class III antiar-
rhythmic drugs (pb0.001, Table 5). Strong independent predictors of
sinus rhythm were AF lasting less than 48 h, absence of comorbidities
(Table 2) and younger age (Fig. 1). Overall reduction of admission
with aggressive versus standard approach accounts for 60%, 50% versusTable 3
Association between clinical variables and hospital admission at univariate and multi-
variate analyses.
Univariate analysis Multivariate analysis
OR Confidence
interval 95%
p OR Confidence
interval 95%
p
Sinus rhythm 8.993 7.186–11.253 b0.001 6.047 4.382–8.445 b0.001
Age 1.040 1.030–1.051 b0.001 1.022 1.010–1.033 b0.001
AF lasting b48 h 0.170 0.137–0.210 b0.001 0.694 0.502–0.960 b0.001
Comorbidities 0.435 0.356–0.531 b0.001 0.544 0.432–0.684 b0.001
Diabetes mellitus 0.489 0.364–0.657 b0.001 0.616 0.437–0.868 0.006
Male gender 1.093 0.898–1.330 0.376 – – –
Please cite this article as: Conti A, et al, Aggressive approach and outcom
diol (2011), doi:10.1016/j.ijcard.2011.09.07429%, respectively (pb0.001, Fig. 2). Independent predictors of hospital-
ization were lack of sinus rhythm, AF lasting more than 48 h, presence
of comorbidities (Table 3) and older age (Fig. 4). Consistent with our
findings, previous studies have reported that hypertension accounts
for more than one-half in patients presenting AF, and aggressive
approach could result in improving sinus rhythm and reducing admis-
sion. In fact, in the Manitoba Follow-up study, prevalence of hyperten-
sionwas 53%, and the risk of AF in hypertensive subjects was increased
by 1.4 times, while increased by 1.9 times in the Framingham Heart
Study [18]. Because of its high prevalence in the population, hyperten-
sion independently accounts for more AF cases than any other risk fac-
tor [18,19]. Several other studies stated Observation Units as a rational
choice for improving the utilization of health care resources [20], espe-
cially for successful treatment of chest pain [21], asthma [22], syncope
[23] and eventually for treatment of AF, in order to reduce in-hospital
stay [24]. Nonetheless no strategy to pursue normal sinus rhythm
including antiarrhythmic drug therapy, conversion and ablation has
definitely being shown to reduce the risk of stroke and hospitalization
[25], in our setting physicians were strongly invited to consider phar-
macological conversion as first line treatment [9]. Hence, among pa-
tients who recovered sinus rhythm, pharmacological approach was
the most representative therapeutic strategy (55%). However, in our
study we observed greater percentage of successful electrical treat-
ment through the 6-year period (8% in group 1 versus 21% in group
2; pb0.001). This fact related with electrical approach as rescue treat-
ment when pharmacological treatment failed. Recently, an observa-
tional survey of management of AF in real life has shown therapeutic
success was likely associated with rhythm-control. In this large survey
enrolling 5171 patients therapeutic success was 54% overall (rhythm
control 60% versus rate control 47%) a result driven by control of AF.
Duration of AF, older age and heart failure predicted permanent AFTable 4
Modalities of rhythm conversion in patients enrolled in the study. Class AAD, Vaughan–
Williams Class of Anti Arrhythmic Drugs.
Total
n=1739
Group 1
n=591
p Group 2
n=1148
Sinus rhythm (n, %) 1039 (60%) 330 (56%) 0.018 709 (62%)
Spontaneous conversion (n, %) 289 (28%) 77 (24%) 0.028 212 (30%)
Electrical conversion (n, %) 175 (17%) 27 (8%) b0.001 148 (21%)
Pharmacological conversion (n, %) 574 (55%) 225 (68%) b0.001 349 (49%)
Class IC AAD (n, %) 412 (72%) 135 (60%) 277 (79%)
Class III AAD (n, %) 162 (28%) 90 (40%) 72 (21%)
e in patients presenting atrial fibrillation and hypertension, Int J Car-
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Fig. 2. Patients enrolled in group 1 and 2 (black bars); patients admitted (gray bars).
*pb0.001.
Table 5
Modalities of rhythm conversion in patients with atrial fibrillation lasting less than
48 h enrolled in the study. Class AAD, Vaughan–Williams Class of Anti-Arrhythmic
Drugs.
Total
n=1071
Group 1
n=320
p Group 2
n=751
Sinus rhythm (n, %) 950 (89%) 280 (88%) 0.460 670 (89%)
Spontaneous conversion (n, %) 249 (26%) 64 (23%) 0.129 185 (28%)
Electrical conversion (n, %) 160 (17%) 20 (7%) b0.001 140 (21%)
Pharmacological conversion (n, %) 541 (57%) 196 (70%) b0.001 345 (51%)
Class IC AAD (n, %) 394 (73%) 120 (61%) 274 (79%)
Class III AAD (n, %) 147 (27%) 76 (39%) 71 (21%)
4 A. Conti et al. / International Journal of Cardiology xxx (2011) xxx–xxx[4]. Prevalence of AF and hospitalizations for AF increased in recent
years [26,27]; indeed, a report of the American Heart Association
showed hospitalizations, with AF as the first-listed diagnosis, increased
by 34% from1996 to 2001 [25]. This trend appears related to the chang-
ing practice pattern with AF management [28] rather than changes
over time in the distribution of age, sex, and comorbidities [27,29].
As a consequence, AF is a costly public health problem, with hospitali-
zations as the primary cost driver [30] especially in western countries
[31,32]. To date, avoiding hospital admissions becomes mandatory.
In our series, aggressive approach to rhythm conversion was planned
to reduce admission to hospital. Primary part of the plan considered
adherence to guidelines and appropriateness in administration of anti-
arrhythmic drugs (Fig. 2). Previous trials demonstrated antiarrhythmic
drugs succeeded in reducing admissions [13,33] also in patients with
structural heart disease [34]. In addition, electrical treatment was con-
sidered as rescue treatment after failure of pharmacological approach.
Finally, in present study, a substantial portion of patients of group 2
with comorbidities or lack of rhythm control, in whom admission
might be considered a real option, was evaluated in Outpatient Clinic
for optimization of rate control or rhythm control in order to reduce
frequency and severity of AF symptoms, avoiding current admission.Class IC 
AAD
394 (73%)
Class III 
AAD
147 (27%)
Rhythm 
control
950 (89%)
Spontaneous 
conversion
249 (26%) 
Pharmacological 
conversion
541 (57%)
DC shock 
160 (17%)
AF <48 hours 
1,071 (62%)
Rate control 
121(11%)
Fig. 3. Diagram of management in patients presenting with atrial fibrillation lasting less
than 48 h enrolled in the study. Class ADD, Vaughan–Williams Class of Anti-Arrhythmic
Drugs.
Please cite this article as: Conti A, et al, Aggressive approach and outcom
diol (2011), doi:10.1016/j.ijcard.2011.09.074Consistent with this strategy a recent large in-hospital observational
registry of AF patients showed that hospitalizations within 2 years
after AF diagnosis were associated with increased AF symptom burden
and with known limitations of contemporary drug therapy. In this
analysis concerning a real world population, the authors suggested
that interventions to reduce hospitalization should improve quality of
life by reducing symptom frequency and severity rather than just pre-
venting AF recurrences [35]. Although criteria for submission to the
Outpatient Clinic were not standardized and at discretion of the emer-
gency physician on duty, we consider this option a remarkable step to
avoid current and further hospital admissions.5. Conclusion
Aggressive pharmacological and electrical approach in patients
presenting AF and hypertension significantly improved rhythm
conversion overall up to two-third. In those patients presenting AF
lasting less than 48 h sinus rhythm accounts for four-fifth. Large
part of patients achieved sinus rhythm by pharmacological treatment
strategy, mostly by class IC antiarrhythmic drugs. Admissions eventu-
ally reduced up to 60%.Acknowledgement
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with the Principles of Ethical Publishing in the International Journal
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Fig. 4. Association between decades of age and admission to hospital in patients with
atrial fibrillation and hypertension enrolled in the study (n=1739).
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